焦点速递！民生证券给予梅花生物推荐评级，2025年半年报点评：主业深耕不辍，全球化赋能添力，长期发展空间可期

Core Viewpoint - Minsheng Securities has issued a recommendation rating for Meihua Biological (600873.SH) based on its stable revenue growth and strategic initiatives in overseas expansion and acquisitions [2] Group 1: Revenue and Market Performance - The increase in lysine volume and price has contributed to overall stable revenue growth for Meihua Biological [2] - The company is focusing on deepening its core business while exploring new opportunities through international expansion and acquisitions [2] Group 2: Strategic Initiatives - Meihua Biological is embarking on a new journey by leveraging overseas markets and acquisitions to enhance its business capabilities [2]